Chocolate Touch DCB successful in head-to-head trial in femoropopliteal disease

WASHINGTON — A new study supports the safety and effectiveness of the Chocolate Touch drug-coated balloon for the treatment of symptomatic peripheral arterial disease with lesions in superficial femoral and popliteal arteries.
The second-generation Chocolate Touch DCB (TriReme Medical) met both noninferiority endpoints for safety and efficacy and was more effective than the first-generation Lutonix DCB (BD) at 12 months, Mehdi H. Shishehbor, DO, MPH, PhD, president of the Harrington Heart & Vascular Institute at University Hospitals of Cleveland and researcher for the CHOCOLATE TOUCH

WASHINGTON — A new study supports the safety and effectiveness of the Chocolate Touch drug-coated balloon for the treatment of symptomatic peripheral arterial disease with lesions in superficial femoral and popliteal arteries.
The second-generation Chocolate Touch DCB (TriReme Medical) met both noninferiority endpoints for safety and efficacy and was more effective than the first-generation Lutonix DCB (BD) at 12 months, Mehdi H. Shishehbor, DO, MPH, PhD, president of the Harrington Heart & Vascular Institute at University Hospitals of Cleveland and researcher for the CHOCOLATE TOUCH